|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Sorrento_Therapeutics_(Canada)_Inc.
gptkb:Atea_Pharmaceuticals
|
|
gptkbp:business_model
|
gptkb:Research_and_development
|
|
gptkbp:ceo
|
Dr. Robert A. Mc Nally
|
|
gptkbp:clinical_trial
|
Ongoing clinical studies
Phase 2 trials for COVID-19
|
|
gptkbp:collaborations
|
gptkb:Research_Institute
|
|
gptkbp:focuses_on
|
antiviral therapies
|
|
gptkbp:founded
|
gptkb:2018
|
|
gptkbp:goal
|
Develop effective antiviral drugs
|
|
gptkbp:headquarters
|
gptkb:New_York,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viral Clear Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:investment
|
Various venture capital firms
|
|
gptkbp:market
|
Global pharmaceutical market
|
|
gptkbp:notable_products
|
Viral Clear (favipiravir)
|
|
gptkbp:partnership
|
gptkb:University_of_California,_San_Diego
|
|
gptkbp:products
|
Viral Clear for COVID-19 treatment
|
|
gptkbp:regulatory_compliance
|
FDA approval process
|
|
gptkbp:research_focus
|
RNA viruses
|
|
gptkbp:target_market
|
Healthcare providers
|
|
gptkbp:technology
|
Drug repurposing
|
|
gptkbp:type
|
Private company
|
|
gptkbp:website
|
www.viralclear.com
|